Breast cancer (BrCa) occurs in 1 of 9 women. The strongest predictor of recurrent disease is the number of tumor positive axillary nodes at diagnosis. Women with 4-10 positive lymph nodes have a 70 percent chance of recurrence within 10 years and women with 11-20 positive nodes have an 82 percent chance of recurrence within ten years. New non-toxic strategies are needed to improve overall survival and progression free- survival. Since HER2/neu (HER2) is over expressed in BrCa, HER2 is ideal target for anti-CD3 activated T cells (ATC) """"""""armed"""""""" with bispecific antibodies (BiAb) which bind to CD3 on T cells and HER2 protein on tumor cells to augment specific cytotoxicity. Our preliminary studies show that ATC from normal subjects and cancer patients can be expanded after anti-CD3 activation in low dose IL-2 and then armed with chemically heteroconjugated anti- CD3 x anti-HER2 (Her2Bi). The armed ATC are highly cytotoxic to HER2+ MCF-7 and SK-BR-3 cell lines at effector to target ratios as low as 3:1. This phase I/II trial using immunotherapy (IT) consisting of multiple infusions of Her2Bi armed ATC, IL-2, and GM-CSF will involve women with HER2 positive and negative biopsies.
The aims of this proposal are: 1) Perform a phase I dose-escalation clinical trial in women with stable, HER2/neu positive or HER2/neu negative stage IV breast cancer with measurable or evaluable disease, in order to determine the maximum tolerated dose (MTD) for HER2Bi-armed ATC given in combination with IL-2 and GM-CSF. Each patient will receive 8 infusions (twice a week for 4 weeks) with dose levels of 2.5, 5, 10, 20, and 40 x 109 HER2Bi-armed ATC or until the dose is technically limiting. Fifteen to 30 patients are needed for the phase I; 2) Perform a phase II study using the MTD determined in Aim 1 in 33 women with stable, measurable or evaluable stage IV breast cancer and whose tumors demonstrate 2+ or 3+ HER2/neu overexpression to define the toxicity profile at the MTD, evaluate clinical responses; and to estimate overall and progression free survival; 3) Evaluate in vivo/in vitro clinical parameters in the phase I and II studies to develop in vitro correleates of clinical events by: a) monitoring serum HER2/neu receptors (sHER2r), CA27-29, carcinoembryonic antigen (CEA) and antibody responses to mouse proteins (HAMA); and b) sequentially monitoring immune responses to evaluate immune modulation induced by IT; and 4) Determine if HER2Bi armed-ATC traffic to metastatic tumor sites in selected HER2/neu positive patients who have evaluable or measurable disease. The studies will provide immunologic insights as to whether armed ATC can alter the immune systems of patients with both HER2+.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Xie, Heng
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Lum, Lawrence G; Thakur, Archana; Kondadasula, Sri Vidya et al. (2016) Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity. Biol Blood Marrow Transplant 22:869-78
Bhutani, Divaya; Lum, Lawrence G (2015) Activated T cells armed with bispecific antibodies kill tumor targets. Curr Opin Hematol 22:476-83
Lum, Lawrence G; Thakur, Archana; Al-Kadhimi, Zaid et al. (2015) Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res 21:2305-14
Lum, L G; Thakur, A; Pray, C et al. (2014) Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. Bone Marrow Transplant 49:73-9
Yano, Hiroshi; Thakur, Archana; Tomaszewski, Elyse N et al. (2014) Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med 12:191
Zitron, Ian M; Thakur, Archana; Norkina, Oxana et al. (2013) Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 13:83
Lum, Lawrence G; Thakur, Archana; Liu, Qin et al. (2013) CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 19:925-33
Thakur, Archana; Vaishampayan, Ulka; Lum, Lawrence G (2013) Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) 5:569-90
Thakur, Archana; Schalk, Dana; Tomaszewski, Elyse et al. (2013) Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. J Transl Med 11:35
Thakur, Archana; Schalk, Dana; Sarkar, Sanila H et al. (2012) A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother 61:497-509

Showing the most recent 10 out of 26 publications